Dominant negative mutation in oxalate transporter


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
11 2022
Historique:
received: 11 10 2021
accepted: 11 01 2022
pubmed: 5 2 2022
medline: 26 10 2022
entrez: 4 2 2022
Statut: ppublish

Résumé

Nephrolithiasis (NL) is a complex multifactorial disease affecting up to 10%-20% of the human population and causing a significant burden on public health systems worldwide. It results from a combination of environmental and genetic factors. Hyperoxaluria is a major risk factor for NL. We used a whole exome-based approach in a patient with calcium oxalate NL. The effects of the mutation were characterised using cell culture and in silico analyses. We identified a rare heterozygous missense mutation (c.1519C>T/p.R507W) in the Our study is in line with previous observations made in the mouse showing that

Sections du résumé

BACKGROUND
Nephrolithiasis (NL) is a complex multifactorial disease affecting up to 10%-20% of the human population and causing a significant burden on public health systems worldwide. It results from a combination of environmental and genetic factors. Hyperoxaluria is a major risk factor for NL.
METHODS
We used a whole exome-based approach in a patient with calcium oxalate NL. The effects of the mutation were characterised using cell culture and in silico analyses.
RESULTS
We identified a rare heterozygous missense mutation (c.1519C>T/p.R507W) in the
CONCLUSION
Our study is in line with previous observations made in the mouse showing that

Identifiants

pubmed: 35115415
pii: jmedgenet-2021-108256
doi: 10.1136/jmedgenet-2021-108256
pmc: PMC9346097
mid: NIHMS1807775
doi:

Substances chimiques

Antiporters 0
Calcium SY7Q814VUP
Calcium Oxalate 2612HC57YE
Oxalates 0
Sulfate Transporters 0
SLC26A6 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1035-1043

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK033793
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Nat Protoc. 2016 Jan;11(1):1-9
pubmed: 26633127
Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G719-28
pubmed: 16373425
Am J Clin Nutr. 1973 Jul;26(7):758-65
pubmed: 4576881
J Biol Chem. 2002 Sep 13;277(37):33963-7
pubmed: 12119287
J Urol. 2016 Jul;196(1):118-23
pubmed: 26812303
J Am Soc Nephrol. 2019 Feb 6;:
pubmed: 30728179
Am J Physiol Cell Physiol. 2016 Dec 1;311(6):C866-C873
pubmed: 27681177
J Am Soc Nephrol. 2013 Oct;24(10):1617-26
pubmed: 23833257
Kidney Int. 2001 Jan;59(1):270-6
pubmed: 11135080
Am J Kidney Dis. 2008 Dec;52(6):1096-103
pubmed: 18951670
BJU Int. 2016 Nov;118(5):785-789
pubmed: 27128735
J Clin Invest. 2005 Oct;115(10):2598-608
pubmed: 16200192
JAMA. 2013 Jul 24;310(4):408-15
pubmed: 23917291
Eur J Endocrinol. 2009 Feb;160(2):283-8
pubmed: 19029225
Nephron. 1980;26(3):105-10
pubmed: 7412965
Nat Commun. 2019 May 2;10(1):2032
pubmed: 31048734
Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2133-40
pubmed: 25341724
Rev Urol. 2010 Spring;12(2-3):e86-96
pubmed: 20811557
Nat Genet. 2006 Apr;38(4):474-8
pubmed: 16532010
N Engl J Med. 2013 Aug 15;369(7):649-58
pubmed: 23944302
BMJ. 2012 Aug 29;345:e5287
pubmed: 22936784
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Kidney Int. 2008 Feb;73(4):489-96
pubmed: 18059457
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9425-30
pubmed: 11459928
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
J Am Soc Nephrol. 2011 Dec;22(12):2247-55
pubmed: 22021714
Elife. 2019 Jul 24;8:
pubmed: 31339488
Front Pharmacol. 2020 Apr 07;11:405
pubmed: 32317970

Auteurs

Nicolas Cornière (N)

Department of Precision Médicine for Metabolic and Renal Diseases, CHU Amiens Picardie, Université de Picardie Jules Verne, Amiens, France.
UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

R Brent Thomson (RB)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Stéphanie Thauvin (S)

Plateau de Recherche ODHIR, AURAR, Saint-Gilles-les-Bains, Réunion.

Bruno O Villoutreix (BO)

UMR 1141, INSERM, Paris, Île-de-France, France.

Sophie Karp (S)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Diane W Dynia (DW)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Sarah Burlein (S)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Lennart Brinkmann (L)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Alaa Badreddine (A)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Aurélie Dechaume (A)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Mehdi Derhourhi (M)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Emmanuelle Durand (E)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Emmanuel Vaillant (E)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Philippe Froguel (P)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Régine Chambrey (R)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.
Plateau de Recherche ODHIR, AURAR, Saint-Gilles-les-Bains, Réunion.

Peter S Aronson (PS)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Amélie Bonnefond (A)

UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Dominique Eladari (D)

Department of Precision Médicine for Metabolic and Renal Diseases, CHU Amiens Picardie, Université de Picardie Jules Verne, Amiens, France dominique.eladari@inserm.fr.
UMR1283, INSERM; CNRS; University of Lille, Lille, Hauts de France, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH